Promising targeted therapy for tough breast cancer hits roadblock

NCT ID NCT04251533

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 5 times

Summary

This study tested whether adding the drug alpelisib to standard chemotherapy (nab-paclitaxel) could help people with advanced triple negative breast cancer that has specific genetic changes (PIK3CA mutation or PTEN loss). The trial enrolled 137 participants but was stopped early. The goal was to see if the combination slowed cancer growth or shrank tumors. Because the study was terminated, final conclusions about effectiveness are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST NEOPLASMS

Contacts and locations

Locations

Hematology and Oncology Clinic

Baton Rouge, Louisiana, 70809, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Novartis Investigative Site

Rosario, Santa Fe Province, S2000KZE, Argentina
Novartis Investigative Site

CABA, C1113AAE, Argentina
Novartis Investigative Site

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site

Nedlands, Western Australia, 6009, Australia
Novartis Investigative Site

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site

Leoben, A 8700, Austria
Novartis Investigative Site

Barretos, São Paulo, 14784 400, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 01317-002, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 04014-002, Brazil
Novartis Investigative Site

Plovdiv, 4004, Bulgaria
Novartis Investigative Site

Hefei, Anhui, 230001, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050011, China
Novartis Investigative Site

Changsha, Hunan, 410013, China
Novartis Investigative Site

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site

Nanchang, Jiangxi, 330009, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Shengyang, Liaoning, 110042, China
Novartis Investigative Site

Shenyang, Liaoning, 110011, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310016, China
Novartis Investigative Site

Dalian, 116000, China
Novartis Investigative Site

Shanghai, 200025, China
Novartis Investigative Site

Tianjin, 300480, China
Novartis Investigative Site

Bogotá, 110221, Colombia
Novartis Investigative Site

Zagreb, 10000, Croatia
Novartis Investigative Site

Saint-Cloud, Hauts De Seine, 92210, France
Novartis Investigative Site

Angers, 49055, France
Novartis Investigative Site

Saint-Herblain, 44805, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site

Essen, 45136, Germany
Novartis Investigative Site

Budapest, 1134, Hungary
Novartis Investigative Site

Faridabad, Haryana, 121 001, India
Novartis Investigative Site

Mumbai, Maharashtra, 400056, India
Novartis Investigative Site

Vellore, Tamil Nadu, 632 004, India
Novartis Investigative Site

Hyderabad, Telangana, 500034, India
Novartis Investigative Site

Tel Aviv, 6423906, Israel
Novartis Investigative Site

Meldola, FC, 47014, Italy
Novartis Investigative Site

Roma, RM, 00128, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Petaling Jaya, Selangor, 46050, Malaysia
Novartis Investigative Site

Kuala Lumpur, 59100, Malaysia
Novartis Investigative Site

Monterrey, Nuevo León, 64460, Mexico
Novartis Investigative Site

Oslo, NO-0407, Norway
Novartis Investigative Site

Trujillo, La Libertad, 13011, Peru
Novartis Investigative Site

Gdynia, 81 519, Poland
Novartis Investigative Site

Opole, 45-061, Poland
Novartis Investigative Site

Poznan, 61 485, Poland
Novartis Investigative Site

Arkhangelsk, 163045, Russia
Novartis Investigative Site

Chelyabinsk, 454048, Russia
Novartis Investigative Site

Moscow, 117997, Russia
Novartis Investigative Site

Moscow, 123056, Russia
Novartis Investigative Site

Saint Petersburg, 196603, Russia
Novartis Investigative Site

Bratislava, 812 50, Slovakia
Novartis Investigative Site

Bratislava, 83310, Slovakia
Novartis Investigative Site

Košice, 041 91, Slovakia
Novartis Investigative Site

Ljubljana, 1000, Slovenia
Novartis Investigative Site

Port Elizabeth, Western Cape, 6045, South Africa
Novartis Investigative Site

Johannesburg, 2196, South Africa
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

Seoul, 06351, South Korea
Novartis Investigative Site

Palma, Balearic Islands, 07120, Spain
Novartis Investigative Site

Badajoz, Extremadura, 06080, Spain
Novartis Investigative Site

Alicante, 03010, Spain
Novartis Investigative Site

Lausanne, 1011, Switzerland
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 10449, Taiwan
Novartis Investigative Site

Istanbul, Fatih, 34098, Turkey (Türkiye)
Novartis Investigative Site

Istanbul, Kadikoy, 34722, Turkey (Türkiye)
Novartis Investigative Site

Nottingham, NG5 1PB, United Kingdom
Novartis Investigative Site

Oxford, OX3 7LE, United Kingdom
Park Nicollet Institute

Saint Louis Park, Minnesota, 55416, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
University of California LA

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.